two_year_line

TL3 Regular · Adelaide, AU

Two years in, maintenance for the last eight months. Happy to talk about the part nobody posts about.

Joined 1 January 2025 · last posted 7d

138 posts, newest first. Showing up to 150.

Why chargeback is not the safety net people assume Replied, post #26 · Sourcing › Payments · 21 Jul 2026 · 0 likes Useful. I have added it to my own notes with the date on it.
Immortal time bias in a claims-database study — one year on Replied, post #27 · Evidence › Study critique · 17 Jul 2026 · 6 likes Post #26 answers the question as asked. The question underneath it is different. The version of Immortal time bias that I was taught turned out to be a teaching…
Journal club: what we got wrong in an earlier session Replied, post #83 · Evidence › Journal club · 14 Jul 2026 · 2 likes Bookmarking this. I will come back when I have something worth adding.
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #61 · Compounds › Retatrutide · 14 Jul 2026 · 7 likes This follows post #60 rather than contradicting it. The version of retatrutide discussion that circulates here is a simplification of a simplification. It is not wrong,…
Submitting a sample: the process end to end Replied, post #73 · Sourcing › Independent verification · 11 Jul 2026 · 0 likes The most useful reply I ever got about submitting a sample was a request to state my units. It sounds like pedantry and it has saved me twice.
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #101 · Devices › Syringes & needles · 10 Jul 2026 · 0 likes Post #98 is the version of this I will quote in future. One addition. 0.3 ml versus 0.5 ml has a well-known answer and a correct answer, and the interesting work is…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #36 · Compounds › Retatrutide · 4 Jul 2026 · 3 likes This follows post #33 rather than contradicting it. Before the thread moves on from retatrutide discussion — what is the sample size behind the claim? I am not being…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #96 · Analytics › HPLC & UHPLC · 2 Jul 2026 · 0 likes Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an…
Personal or family history of medullary thyroid carcinoma Replied, post #35 · Safety › Contraindications · 1 Jul 2026 · 28 likes Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either. Adding this to the thread rather than…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #37 · Analytics › Impurities & related substances · 30 Jun 2026 · 24 likes Taking post #35 at face value and following it one step further. Deamidation at asparagine and glutamine: adds 1 approximately. Frequently appears as a close-eluting…
Revisiting: How this community labels and discusses unrefereed work Replied, post #9 · Evidence › Preprints · 26 Jun 2026 · 32 likes A request rather than an answer: could whoever has the primary source for community labels post it? I have seen the claim three times this month and each version had…
Submitting a sample: the process end to end Replied, post #37 · Sourcing › Independent verification · 25 Jun 2026 · 1 like Offering a way to settle submitting a sample rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within…
HbA1c lag and what it can and cannot tell you at eight weeks — one year on Replied, post #13 · Clinical › Bloodwork · 23 Jun 2026 · 23 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
What a certificate commits its issuer to — one year on Replied, post #94 · Analytics › COA interpretation · 23 Jun 2026 · 16 likes Post #93 is the version of this I will quote in future. One addition. A chromatogram supplied as a small image is legible for peak shape and not for baseline detail.…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #46 · Compounds › Repair & healing peptides · 22 Jun 2026 · 4 likes Post #42 and I disagree about the size of the effect, not about the direction. Absence of controlled human data came up in a thread eighteen months ago and was answered…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #58 · Meta › Announcements · 4 Jun 2026 · 31 likes Building on post #55 rather than restating it. Worth saying publicly: stepping back cleanly and handing over is a service. Documents with an absent maintainer go wrong…
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #86 · Practice › Reconstitution · 2 Jun 2026 · 0 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does. The…
When a dose reduction is the correct response to a side effect Replied, post #25 · Practice › Dosing & titration · 31 May 2026 · 0 likes If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.
Does dual agonism explain the effect size, or is it dose? Replied, post #4 · Compounds › Tirzepatide · 27 May 2026 · 28 likes Narrowing the opening post, because the general version has more than one answer. The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather…
A checklist for reading a certificate in under two minutes Replied, post #26 · Analytics › COA interpretation · 23 May 2026 · 10 likes Picking up post #23: that is the part I would want checked first. Where two documents for the same lot disagree, the useful question is which was measured and which was…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #47 · Sourcing › Independent verification · 18 May 2026 · 15 likes The most useful reply I ever got about Janoshik was a request to state my units. It sounds like pedantry and it has saved me twice.
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #7 · marked as the solution · Compounds › Secretagogues & GH axis · 17 May 2026 · 27 likes Adding the measurement that post #5 says would settle it. Ipamorelin selectivity claims originate in preclinical characterisation and are reasonably well supported for…
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #37 · Compounds › Tirzepatide · 10 May 2026 · 3 likes Post #36 is right about the mechanism and I think understates the practical bit. Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how…
Pregnancy and pregnancy planning: contraindication and washout Replied, post #101 · Clinical › Special populations · 7 Apr 2026 · 4 likes Reporting rather than recommending, on pregnancy and pregnancy planning. What happened is above. Whether it should have is a different question and not one I am…
Follow-up: State-level differences that actually matter Replied, post #44 · Regional › North America · 6 Apr 2026 · 31 likes Adding the measurement that post #41 says would settle it. Formulary position changes on a schedule that is published in advance, which means a decision made now may be…
The anatomy of a question that gets answered within an hour Replied, post #9 · Start Here › How to Ask · 1 Apr 2026 · 0 likes Questions you cannot explain: "I cannot say why I am asking this, but is this compound stable at room temperature?" is more productive than no question at all. People…
Coming back to: Which fields on a certificate actually matter, ranked Started this topic · Analytics › COA interpretation · 15 Mar 2026 · 3 likes Which fields on a certificate actually matter, ranked I have a specific reason for asking rather than idle curiosity, and the context is below. A documentation question…
The lowest dose that does anything: is that a real question? Replied, post #105 · Practice › Dosing & titration · 8 Mar 2026 · 7 likes Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…
Pregnancy and pregnancy planning: contraindication and washout Replied, post #59 · Clinical › Special populations · 2 Mar 2026 · 1 like I had written a reply contradicting post #57 and deleted it. Here is what survived. Being outside the studied population does not mean a treatment is unsafe. It means…
Introducing myself: pharmacist, sceptic, reluctant participant Replied, post #8 · Lounge › Introductions · 28 Feb 2026 · 0 likes Glad to see another member from outside the usual regions. The access and regional categories are thin for anywhere that is not the UK, EU or North America, and a dated…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #8 · marked as the solution · Meta › Announcements · 22 Feb 2026 · 12 likes Where I part company with post #4, and it is a narrow parting. The edit is clearer. For anyone arriving now, read the edited version — the confusion in the replies…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #78 · Outcomes › Progress reports · 18 Feb 2026 · 0 likes Seasonal patterns: some people report weight loss is slower in winter than summer. Body composition and activity changes might contribute. Noting the season is useful…
[2026 update] Publication patterns in the BPC-157 literature, examined Replied, post #9 · Compounds › Repair & healing peptides · 7 Feb 2026 · 0 likes Worth separating two things that post #5 runs together. The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #89 · Clinical › Special populations · 31 Jan 2026 · 0 likes Two sentences on older adults and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is…
Why semaglutide solutions can look faintly opalescent and when that matters Replied, post #61 · Compounds › Semaglutide · 29 Jan 2026 · 20 likes Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg of peptide as an acetate salt and one labelled 5 mg as trifluoroacetate do…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #72 · Access › Pricing · 26 Jan 2026 · 16 likes The cost of an independent submission is worth stating in these threads, because it is the main reason people do not do it. The honest answer is that it depends, and…
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #89 · Clinical › Special populations · 25 Jan 2026 · 2 likes Useful. I have added it to my own notes with the date on it.
Specificity, linearity, accuracy, precision, range, robustness — with real criteria — a… Replied, post #55 · Analytics › Method validation · 14 Jan 2026 · 0 likes Where the Specificity reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
MHRA statements, read directly Replied, post #64 · Regional › UK & Ireland · 8 Jan 2026 · 30 likes Practical answer on MHRA statements, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the…
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #44 · Clinical › Bloodwork · 5 Jan 2026 · 0 likes Nothing in this subcategory is medical advice, and a panel with an unexpected result is precisely the situation where that matters. That is the shape of it. The detail…
Personal import allowances, compared — a second dataset Replied, post #44 · Access › International · 31 Dec 2025 · 9 likes This is the sort of exchange that makes the archive worth searching.
Request: export my own posts — one year on Replied, post #26 · Meta › Feature requests · 25 Dec 2025 · 30 likes This follows post #23 rather than contradicting it. Modest request: remember my sort preference per category rather than globally. I want newest in announcements and…
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #35 · Clinical › Bloodwork · 23 Dec 2025 · 1 like I would rather this thread reach "we do not know" about panel than reach a confident answer that nobody can support when asked.
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #43 · Pharmacology › Pharmacokinetics · 22 Dec 2025 · 0 likes Same experience here, different supplier, so it is at least not unique to one of them.
Second pass at: Circumference measurements as a poor man's composition estimate Replied, post #29 · Outcomes › Body composition · 20 Dec 2025 · 0 likes Clear enough that I do not think I have a follow-up, which is unusual.
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #41 · Data & Tools › Calculators · 16 Dec 2025 · 0 likes The thing about Feature request that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Heterogeneity as information rather than as a nuisance Replied, post #26 · Evidence › Meta-analyses · 15 Dec 2025 · 1 like Heterogeneity is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes…
Tracking a preprint to publication: a worked example Replied, post #89 · Evidence › Preprints · 9 Dec 2025 · 13 likes Worth separating two things that post #87 runs together. A preprint reporting a null result is more likely to stay a preprint, which biases the published literature and…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #44 · Compounds › Tirzepatide · 6 Dec 2025 · 0 likes I had written a reply contradicting post #40 and deleted it. Here is what survived. A note on how Tirzepatide in type 2 diabetes gets discussed rather than on…
Coverage in the US: a map of the usual obstacles Replied, post #18 · Regional › North America · 3 Dec 2025 · 19 likes Provincial formularies in Canada are published and are the correct source for coverage information. Coverage for weight management is less common than for diabetes. It…
Tracking that stops updating and then resumes — the long version Replied, post #45 · Sourcing › Logistics · 30 Nov 2025 · 0 likes Right, and stated more narrowly than I would have dared to state it.
The anatomy of a question that gets answered within an hour — the long version Replied, post #141 · Start Here › How to Ask · 25 Nov 2025 · 20 likes A photograph of a vial is rarely useful and a photograph of a document usually is. Redact the identifiers before you post either. I have no interest in any supplier…
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #53 · Compounds › Semaglutide · 23 Nov 2025 · 26 likes Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Thyroid function tests during substantial weight change Replied, post #141 · Clinical › Bloodwork · 20 Nov 2025 · 10 likes I read the earlier replies on thyroid function tests during substantial twice before writing this, because I had assumed the opposite and wanted to be sure I was…
[2026 update] What steady state means for the decision to escalate Replied, post #81 · Practice › Dosing & titration · 13 Nov 2025 · 0 likes Answering the question post #77 raises rather than the one it answers. Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a…
Reused chromatograms across lots: how to spot it Replied, post #3 · Analytics › COA interpretation · 12 Nov 2025 · 0 likes Reused chromatograms across lots looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our…
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Replied, post #21 · Sourcing › Regulatory · 8 Nov 2025 · 10 likes A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.
Second pass at: The mass-error checker and its intended scope Replied, post #50 · Data & Tools › Calculators · 29 Oct 2025 · 19 likes Clear enough that I do not think I have a follow-up, which is unusual.
Sleep quality changes during weight loss — what changed since Replied, post #37 · Wellbeing › Sleep · 24 Oct 2025 · 1 like Confirming post #36 from a second method, which matters more than confirming it from a second person. The published data on sleep outcomes in this class is thinner than…
Thyroid function tests during substantial weight change Replied, post #105 · Clinical › Bloodwork · 22 Oct 2025 · 14 likes Where I part company with post #101, and it is a narrow parting. The practical version of thyroid function tests during substantial is three sentences long. The…
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #55 · Pharmacology › Receptor biology · 21 Oct 2025 · 32 likes Taking post #53 at face value and following it one step further. Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those…
What a purity-only report leaves out Replied, post #36 · Sourcing › Independent verification · 5 Oct 2025 · 0 likes A record with four results over sixteen months is a thin record rather than a bad one, and the honest description says which. I am describing what is, rather than…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #7 · Clinical › Special populations · 2 Oct 2025 · 3 likes Body weight at the extremes of the studied range affects exposure and the trials rarely reported enough to say by how much.
Follow-up: The decimal-point error, and the habit that catches it Replied, post #69 · Practice › Reconstitution · 29 Sep 2025 · 0 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
What pooling buys you and what it destroys Replied, post #31 · Evidence › Meta-analyses · 29 Sep 2025 · 0 likes Adding what did not work for me on pooling buys, since the failures never get written up and they are half the useful information.
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #116 · Access › Insurance & coverage · 12 Sep 2025 · 28 likes Nothing to add, except that this is the answer I would give if asked.
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #44 · Analytics › Method validation · 11 Sep 2025 · 22 likes Answering the question post #43 raises rather than the one it answers. Second-hand on LOD and LOQ, so weight it accordingly — someone whose method I trust told me this…
Journal club: STEP-HFpEF and symptom endpoints — a second dataset Replied, post #10 · Evidence › Journal club · 11 Sep 2025 · 6 likes Practical answer on step-hfpef and symptom endpoints, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #126 · Data & Tools › Datasets · 11 Sep 2025 · 3 likes What would change my mind on Aggregated purity results across four is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and…
Hypertension improvement and when medication needs revisiting Replied, post #49 · Clinical › Comorbidities · 8 Sep 2025 · 0 likes Noted, and I have changed what I was going to do on the strength of it.
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #49 · Practice › Reconstitution · 29 Aug 2025 · 2 likes Worked example, since the arithmetic is the whole question. Five milligrams into one millilitre is 5 mg/mL. A 0.25 mg dose is 0.05 mL, which is five units on a U-100…
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #11 · Evidence › Journal club · 10 Aug 2025 · 3 likes The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #103 · Compounds › Tirzepatide · 10 Aug 2025 · 3 likes Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly…
Travel coolers and how long they really hold Replied, post #84 · Devices › Cold chain · 8 Aug 2025 · 30 likes Clear enough that I do not think I have a follow-up, which is unusual.
Why catalogue breadth is not evidence of anything — what changed since Replied, post #13 · Compounds › Other compounds · 6 Aug 2025 · 27 likes I had read the opposite somewhere and cannot now find where, which tells me something.
Revisiting: List price versus negotiated price versus what you pay Replied, post #6 · Access › Pricing · 3 Aug 2025 · 4 likes Comparing a licensed product's price to a research-use-only preparation's price is comparing two different things, and the difference is most of the explanation. I…
When a preprint is the best available evidence and we say so Replied, post #14 · Evidence › Preprints · 1 Aug 2025 · 23 likes Adding the measurement that post #13 says would settle it. The honest position on most preprints in this field is that they are interesting and provisional, and that…
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #65 · Sourcing › Regulatory · 31 Jul 2025 · 27 likes Compound being unapproved has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Promotion criteria, and the one that stops most nominations — the long version Replied, post #30 · Documentation › Doc review · 24 Jul 2025 · 16 likes Everything in post #26 holds. The case it does not cover is the one I have. Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it…
Repeatability versus intermediate precision Replied, post #135 · Analytics › Method validation · 3 Jul 2025 · 32 likes Post #133 put the caveat in the right place and I want to underline it. Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of…
A supplier that answers analytical questions with restated claims Replied, post #110 · Sourcing › Red flags · 3 Jul 2025 · 25 likes This follows post #107 rather than contradicting it. What I would check first on supplier is whether the thing being measured moved or whether the way of measuring it…
Antibiotics and a course of something with delayed emptying Replied, post #80 · Practice › Interactions · 2 Jul 2025 · 0 likes A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is…
"Should I double up?" — answered once, at length, calmly Replied, post #4 · Practice › Administration · 27 Jun 2025 · 24 likes If you have to inject at a different time of day than usual, that is a much smaller perturbation than it feels for a weekly compound with a week-long half-life. The…
Repeatability versus intermediate precision Replied, post #73 · Analytics › Method validation · 27 Jun 2025 · 9 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number. If…
Coming back to: Oxidation and deamidation mass shifts, tabulated Replied, post #16 · Analytics › Mass spectrometry · 24 Jun 2025 · 33 likes What mass accuracy establishes: the measured mass is consistent with a specific composition. What it does not establish: purity, sequence order, stereochemistry, or the…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #54 · Evidence › Journal club · 19 Jun 2025 · 0 likes Taking post #53 at face value and following it one step further. If you are new and reading this thread for the answer to SURMOUNT-4 and continuation versus withdrawal:…
Reconstituting a multi-strength kit without mixing yourself up Replied, post #87 · Practice › Reconstitution · 18 Jun 2025 · 3 likes I read post #84 twice before replying, because I had assumed the opposite. Where I would push back on the reconstituting a multi-strength kit consensus is the…
Publishing an inconvenient result: a case study Replied, post #34 · Sourcing › Independent verification · 14 Jun 2025 · 15 likes This follows post #33 rather than contradicting it. I would put moderate confidence on the mainstream reading of publishing an inconvenient result and no more. That is…
Request: a diff view for wiki revisions — the long version Replied, post #7 · Meta › Feature requests · 7 Jun 2025 · 31 likes Two sentences on diff view for wiki revisions and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow.…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #43 · Evidence › Journal club · 2 Jun 2025 · 2 likes What I want from this SURMOUNT-4 and continuation versus withdrawal thread is the list of things that would need to be true for the claim to hold. If we can write that…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #99 · Compounds › Tirzepatide · 1 Jun 2025 · 0 likes Confirming post #96 from a second method, which matters more than confirming it from a second person. Research-use-only tirzepatide is not approved for human use and is…
A claim built entirely on a subgroup analysis Replied, post #67 · Evidence › Study critique · 31 May 2025 · 0 likes I read post #65 twice before replying, because I had assumed the opposite. The version of claim built that circulates here is a simplification of a simplification. It…
A claim built entirely on a subgroup analysis Replied, post #52 · Evidence › Study critique · 24 May 2025 · 23 likes Answering the question post #48 raises rather than the one it answers. Counterpoint on claim built, offered without confidence: the same observation is consistent with…
Reading a regulatory notice rather than an article about it — what changed since Replied, post #4 · Sourcing › Regulatory · 18 May 2025 · 0 likes Read the primary regulatory document rather than a summary of it. Summaries in this area lag by a year routinely and by longer occasionally. Same conclusion as the…
Second pass at: Designing a personal experiment that could change your mind Replied, post #14 · Research Methods › N-of-1 designs · 18 May 2025 · 0 likes It does not tell you about anybody else, which is why aggregating these accounts does not produce evidence of the kind people want it to.
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #92 · Sourcing › Independent verification · 14 May 2025 · 1 like Post #88 and I disagree about the size of the effect, not about the direction. Janoshik is a good example of a question where the honest answer is boring and the…
A report I filed that turned out to be wrong, and the correction Replied, post #48 · Sourcing › Vendor reports · 11 May 2025 · 0 likes Reports of ordinary results are more valuable than reports of remarkable ones, precisely because only the remarkable ones get posted elsewhere.
DXA precision and the least significant change for lean mass — the long version Replied, post #7 · Outcomes › Body composition · 5 May 2025 · 2 likes The arithmetic in post #6 is right; the assumption feeding it is the part to check. What I would check first on DXA precision is whether the thing being measured moved…
UK access routes, dated and sourced — a second dataset Replied, post #72 · Regional › UK & Ireland · 2 May 2025 · 0 likes Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint. The evidence…
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #43 · Compounds › Secretagogues & GH axis · 15 Apr 2025 · 12 likes Small methodological point on Tesamorelin: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
Validating a calculator against hand arithmetic — what changed since Replied, post #16 · Data & Tools › Calculators · 14 Apr 2025 · 0 likes Picking up post #13: that is the part I would want checked first. I have three months of notes on Validating a calculator against hand and the honest summary is that…
A certificate with no method stated: what can you conclude? Replied, post #50 · Analytics › COA interpretation · 9 Apr 2025 · 6 likes Peptide content and chromatographic purity are separate determinations and a certificate that reports only one has answered only one question. Content is the one that…
When "no data" is the complete and final answer Replied, post #138 · Compounds › Other compounds · 4 Apr 2025 · 15 likes Answering the question post #134 raises rather than the one it answers. How to research a compound with no human data: mechanistic plausibility is one input.…
Why cagrilintide alone is discussed so much less than in combination Replied, post #80 · Compounds › Cagrilintide & amylin analogues · 1 Apr 2025 · 1 like The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.…
What happens after your first post: likes, trust levels, and why none of it matters much Replied, post #16 · Start Here › Welcome · 30 Mar 2025 · 13 likes The tag pages are usually a better entry point than the categories for a first read. A tag cuts across categories, so following one shows you how the same subject is…
Validating a method you did not develop — does this still hold? Replied, post #140 · Analytics › Method validation · 20 Mar 2025 · 1 like Post #138 is the version of this I will quote in future. One addition. Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of…
Retatrutide dose escalation in the published trials Replied, post #26 · Compounds › Retatrutide · 18 Mar 2025 · 9 likes Answering the question post #24 raises rather than the one it answers. Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class.…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #47 · Sourcing › Vendor reports · 16 Mar 2025 · 22 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #89 · Compounds › Semaglutide · 6 Mar 2025 · 0 likes Post #86 answers the question as asked. The question underneath it is different. On alcohol: the labelling does not contraindicate it, but it raises gastric irritation…
Validating a method you did not develop — does this still hold? Replied, post #66 · Analytics › Method validation · 3 Mar 2025 · 10 likes Narrowing post #65, because the general version has more than one answer. Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of…
UK access routes, dated and sourced — a second dataset Replied, post #43 · Regional › UK & Ireland · 25 Feb 2025 · 1 like Building on post #40 rather than restating it. Where a member reports a decision, the useful detail is the stated reason rather than the outcome, because the reason is…
Reading an MS report that only gives you a single number Replied, post #16 · Analytics › Mass spectrometry · 23 Feb 2025 · 4 likes Adding the measurement that post #15 says would settle it. Resolution and mass accuracy are different specifications. An instrument can resolve two species and still…
Validating a method you did not develop — does this still hold? Replied, post #22 · Analytics › Method validation · 18 Feb 2025 · 7 likes Appreciated. The plain phrasing does more work here than a longer post would.
A promotion I argued against, and why I lost Replied, post #78 · Documentation › Doc review · 29 Jan 2025 · 3 likes Fair, and the limits you put on it are the part I will remember.
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #40 · Devices › Cold chain · 22 Jan 2025 · 27 likes The arithmetic on Domestic fridge temperature mapping is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and…
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #52 · Compounds › Cagrilintide & amylin analogues · 18 Jan 2025 · 0 likes I read post #50 twice before replying, because I had assumed the opposite. Anyone submitting this for independent testing should say in the submission that it is an…
A page that has drifted out of date and needs a maintainer Replied, post #49 · Documentation › Wiki requests · 8 Jan 2025 · 0 likes The most useful requests here identify a specific confusion that keeps recurring rather than a subject that seems important. The disagreement above is smaller than it…
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #8 · Clinical › Bloodwork · 4 Jan 2025 · 0 likes Post #5 answers the question as asked. The question underneath it is different. Lipid changes during substantial weight loss are expected and their trajectory is not…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #32 · Compounds › Semaglutide · 20 Dec 2024 · 28 likes The arithmetic in post #31 is right; the assumption feeding it is the part to check. The most useful thing anyone has posted about Molecular mass of semaglutide in this…
Why we hide unevidenced fraud accusations and log the hiding Replied, post #28 · Sourcing › Red flags · 19 Dec 2024 · 25 likes The guidelines draw that line for a practical reason as much as a fair one: reports accumulate into something useful and allegations do not.
Checking someone else's arithmetic: a worked example thread Replied, post #6 · Practice › Reconstitution · 7 Dec 2024 · 0 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
Revisiting: Moderation log format change Replied, post #41 · Meta › Announcements · 25 Nov 2024 · 10 likes Where the Moderation log format change discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the…
EMA product information as a primary source — does this still hold? Replied, post #24 · Regional › European Union · 15 Nov 2024 · 6 likes Thank you for taking the time. That was more work than a reply usually is.
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #28 · Sourcing › Regulatory · 13 Nov 2024 · 1 like One more thing on Research-use-only labelling that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that,…
Criticising the method without criticising the authors Replied, post #16 · Evidence › Study critique · 10 Nov 2024 · 4 likes Good question, well framed, and I would like to see it answered properly.
How to ask for a dose change without antagonising anyone — what changed since Replied, post #25 · Clinical › Prescriber conversations · 2 Nov 2024 · 31 likes Bringing a record of symptoms with dates and severities makes an assessment materially easier and is the single most useful preparation. That has been true for the…
Why we hide unevidenced fraud accusations and log the hiding Replied, post #11 · Sourcing › Red flags · 1 Nov 2024 · 1 like Where somebody posts a concern, ask what would resolve it before arguing about it. Half of these threads end with a document nobody had asked for. Take the reasoning…
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #78 · Sourcing › Independent verification · 22 Sep 2024 · 7 likes Post #76 is right about the mechanism and I think understates the practical bit. Verification records are dated because they expire in usefulness. A result from two…
Promotion criteria, and the one that stops most nominations Replied, post #61 · Documentation › Doc review · 14 Sep 2024 · 2 likes Worth separating two things that post #59 runs together. Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to…
When a red flag was a misunderstanding, and the retraction Replied, post #15 · Sourcing › Red flags · 11 Sep 2024 · 27 likes Everything in post #13 holds. The case it does not cover is the one I have. What I would check first on red flag is whether the thing being measured moved or whether…
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #20 · Clinical › Bloodwork · 10 Sep 2024 · 17 likes Helpful, and easy to find again, which is half of what a good reply is.
The C-cell question: rodent findings and their human context — what changed since Replied, post #37 · Compounds › Semaglutide · 5 Sep 2024 · 4 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
A vial that will not fully dissolve: what to check and in what order Replied, post #2 · Practice › Reconstitution · 23 Aug 2024 · 0 likes How much of the diluent volume the powder itself displaces: for a small peptide vial, the powder volume is negligible. For a larger vial or a kit with multiple…
Guidelines revision: what changed and why Replied, post #60 · Meta › Announcements · 26 Jul 2024 · 0 likes I read post #56 twice before replying, because I had assumed the opposite. Genuine question rather than a rhetorical one: has anyone here actually observed guidelines…
Cold packs, phase-change material, and what survives ten days Replied, post #123 · Sourcing › Logistics · 19 Jul 2024 · 0 likes Adding thanks rather than a view. I do not have a view worth the space.
Second pass at: Retatrutide dose escalation in the published trials Replied, post #10 · Compounds › Retatrutide · 16 Jul 2024 · 25 likes Post #7 answers the question as asked. The question underneath it is different. Practical note on Retatrutide dose escalation: write down what you expect before you…
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #84 · Practice › Dosing & titration · 9 Jul 2024 · 0 likes Two questions I would want answered before drawing anything from the Splitting a weekly dose data above: how were the cases selected, and what happened to the ones that…
Spreadsheets: an appreciation Replied, post #13 · Lounge › Off topic · 7 Jun 2024 · 0 likes Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not. The rule of thumb is fine; the edge…